×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

Ñо¿Ö°Ô±±¨¸æÁËÒ»ÖÖ¾ßÓÐϸ°ûÉøÍ¸ÐÔµÄÑ¡ÔñÐÔMETTL3ÄÉĦ¶ûÒÖÖÆ¼ÁUZH1a£¬×÷Õßлл×ðÁú¿­Ê±ºÏ³ÉÁËUZH1aºÍUZH1b

2023-07-05
|
»á¼ûÁ¿£º

54.png

The methylase METTL3 is the writer enzyme of the N6©\methyladenosine (m6A) modification of RNA.

Here researchers report a nanomolar inhibitor of METTL3 (UZH1a) which is selective and cell©\permeable, while its enantiomer UZH1b is essentially inactive. 

The authors thank Medicilon for the synthesis of the UZH1a and UZH1b compounds.

Reference:

Elena V Moroz-Omori, et al. METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular Processes. ChemMedChem. 2021 Oct 6;16(19):3035-3043. doi: 10.1002/cmdc.202100291. 

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿